Note sull'episodio
Today, we’re excited to welcome Allan Bradley to Gravity Encounters. As the Founder and CEO of T-Therapeutics, Allan has had a profound impact on the fields of genomics, monoclonal antibody discovery, and biotech entrepreneurship.
Previously, as the Director of the Wellcome Trust Sanger Institute, Allan played a pivotal role in transforming its genome-sequencing infrastructure into a world-class research centre. His academic research laid the foundation for Kymab Ltd, a humanised antibody discovery company that led to the development of novel therapeutic antibodies, some of which have demonstrated clinical benefits.
Beyond Kymab, Allan co-founded PetMedix, applying cutting-edge antibody technologies to animal health. Earlier in his career, he spun out Lexicon Genetics while at Baylor College of Medicine, which went on to a $1 billion ...